Whitepaper
Drug developers face tremendous pressure to increase efficiency and productivity, and reduce development timelines. At Lonza, focused innovation efforts aimed at addressing these demands have yielded a number of advances in core technologies within the well-established and trusted GS Gene Expression System® platform. The latest advancement, the GS Ori-Go® vector system, harnesses a novel method of glutamine synthetase gene expression control combined with a high-strength gene promoter to control product expression. This results in higher titer and more stable bulk pools, enabling streamlined workflows that can accelerate the timeline from gene to lead clone. High-quality toxicology material can be obtained earlier, thereby helping funding milestones to be met, and contributing towards progress from DNA to IND.